Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.47 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953304 | 0.92 | SMN1; SMN2 (0.57) | SMN1; SMN2FGFR1FLT1PDPK1ITK | |
| SCHEMBL5952675 | 0.91 | PDPK1 (0.47) | SMN1; SMN2FGFR1FLT1PDPK1ITK | |
| SCHEMBL5951853 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2FGFR1FLT1ITKFLT3 | |
| SCHEMBL5951266 | 0.88 | TP53 (0.47) | SMN1; SMN2FGFR1FLT1PDPK1ITK | |
| SCHEMBL5951459 | 0.87 | MAPT (0.46) | SMN1; SMN2FGFR1FLT1ITKFLT3 | |
| SCHEMBL5951726 | 0.87 | KMT2A (0.51) | SMN1; SMN2FGFR1FLT1ITK | |
| SCHEMBL5953264 | 0.86 | FGFR1 (0.46) | SMN1; SMN2FGFR1FLT1PDPK1ITK | |
| SCHEMBL13373559 | 0.85 | CSNK1D (0.49) | SMN1; SMN2FGFR1FLT1PDPK1ITK | |
| SCHEMBL13373498 | 0.85 | FGFR1 (0.44) | SMN1; SMN2FGFR1FLT1PDPK1ITK | |
| SCHEMBL13373609 | 0.85 | USP2 (0.49) | SMN1; SMN2FGFR1FLT1ITKMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | SMN1; SMN2 4210/4885FGFR1 583/4885FLT1 2074/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | SMN1; SMN2 3516/4885FGFR1 254/4885FLT1 1117/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | SMN1; SMN2 1094/4885FGFR1 48/4885FLT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.